A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Subjects Infected With Respiratory Syncytial Virus
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2019
At a glance
- Drugs JNJ 53718678 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 30 Mar 2018 Planned End Date changed from 31 Oct 2019 to 8 Aug 2019.
- 28 Feb 2018 Planned End Date changed from 8 Aug 2019 to 31 Oct 2019.
- 28 Feb 2018 Status changed from not yet recruiting to recruiting.